New Medicines
8 results
Applied filters
Annual medicines planning publication, Prescribing Outlook
22 October 2026Our annual output ‘PO’ supports managed entry and budget planning for new medicines, new indications and medicines with loss of exclusivity in the NHS.
Using our annual medicines planning publication, Prescribing Outlook
22 October 2026Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.
National Homecare Medicines Committee regional contacts
19 October 2026Contact details of the homecare regional specialists within the UK who sit on the National Homecare Medicines Committee (NHMC).
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
Understanding biosimilar and generic market entry
12 September 2025New medicines have several protections against competition. Other factors influence availability of biosimilars or generics after loss of exclusivity.
Understanding data exclusivity and market protection
11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.
Understanding patents
11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.